Biomarker Discovery and Validation: Statistical Considerations

被引:81
|
作者
Ou, Fang-Shu [1 ]
Michiels, Stefan [2 ]
Shyr, Yu [3 ]
Adjei, Alex A. [4 ]
Oberg, Ann L. [1 ]
机构
[1] Mayo Clin, Dept Hlth Sci Res, 200 First St SW, Rochester, MN 55905 USA
[2] Univ Paris Saclay, Dept Biostat & Epidemiol, Labelel Ligue Canc, INSERM,Gustave Roussy,Oncostat U1018,CESP, Villejuif, France
[3] Vanderbilt Univ, Dept Biostat, 221 Kirkland Hall, Nashville, TN 37235 USA
[4] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA
基金
美国国家卫生研究院;
关键词
Biomarker; Exploratory analysis; Confirmation analysis; Clinical trial; CANCER; SPECIMENS; IMPACT; BIAS;
D O I
10.1016/j.jtho.2021.01.1616
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes. Biomarkers have various applications including disease detection, diagnosis, prognosis, prediction of response to intervention, and disease monitoring. In this era of precision medicine, having validated biomarkers to inform clinical decision making is more important than ever. In this article, we discuss best the practices and potential issues in biomarker discovery and validation. We encourage team science partnerships to bring cutting-edge discovery from bench to bedside, leading to improved patient care and outcomes. ? 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:537 / 545
页数:9
相关论文
共 50 条
  • [31] Overview of Omics Biomarker Discovery and Design Considerations for Biomarker-Informed Clinical Trials
    Zhang, Weidong
    Huang, Bo
    Wang, Jing
    Menon, Sandeep
    BIOPHARMACEUTICAL APPLIED STATISTICS SYMPOSIUM, VOL 3: PHARMACEUTICAL APPLICATIONS, 2018, : 23 - 52
  • [32] Analytical Considerations for Mass Spectrometry Profiling in Serum Biomarker Discovery
    Whiteley, Gordon R.
    Colantonio, Simona
    Sacconi, Andrea
    Saul, Richard G.
    CLINICS IN LABORATORY MEDICINE, 2009, 29 (01) : 57 - +
  • [33] Evaluation of Heart Failure Biomarker Tests: A Survey of Statistical Considerations
    De, Arkendra
    Meier, Kristen
    Tang, Rong
    Li, Meijuan
    Gwise, Thomas
    Gomatam, Shanti
    Pennello, Gene
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2013, 6 (04) : 449 - 457
  • [34] Evaluation of Heart Failure Biomarker Tests: A Survey of Statistical Considerations
    Arkendra De
    Kristen Meier
    Rong Tang
    Meijuan Li
    Thomas Gwise
    Shanti Gomatam
    Gene Pennello
    Journal of Cardiovascular Translational Research, 2013, 6 : 449 - 457
  • [35] Statistical considerations and challenges for immuno-oncology biomarker studies
    Li, Lin
    Close, Sandra L.
    Bromley, Christina M.
    Chen, Fang
    Gillis, Laura B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] A statistical framework for biomarker discovery in metabolomic time course data
    Berk, Maurice
    Ebbels, Timothy
    Montana, Giovanni
    BIOINFORMATICS, 2011, 27 (14) : 1979 - 1985
  • [37] The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline
    Paulovich, Amanda G.
    Whiteaker, Jeffrey R.
    Hoofnagle, Andrew N.
    Wang, Pei
    PROTEOMICS CLINICAL APPLICATIONS, 2008, 2 (10-11) : 1386 - 1402
  • [39] Lupus Biomarker Discovery, Validation, Approval, and Impact on Clinical Trials
    Joseph M. Ahearn
    Chau-Ching Liu
    Susan Manzi
    Current Treatment Options in Rheumatology, 2015, 1 (1) : 1 - 9
  • [40] Advances in clinical trial designs for predictive biomarker discovery and validation
    Richard Simon
    Current Breast Cancer Reports, 2009, 1 (4) : 216 - 221